D. McGovern

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

E. Gabriela Chiorean, Daniel D. Von Hoff, Michele Reni et al. · Annals of Oncology · 2016 · 100 citations · Full text

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial

Werner Scheithauer, Ramesh K. Ramanathan, Malcolm J. Moore et al. · Journal of Gastrointestinal Oncology · 2016 · 65 citations · Full text

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

Ramesh K. Ramanathan, David Goldstein, Ron Korn et al. · Annals of Oncology · 2016 · 41 citations · Full text

Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)

Arndt Vogel, Josefine Römmler-Zehrer, Jack Shiansong Li et al. · BMC Cancer · 2016 · 35 citations · Full text

LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival

Margaret A. Tempero, Eileen M. O’Reilly, Eric Van Cutsem et al. · Annals of Oncology · 2021 · 30 citations · Full text

Surgical Oncology, Lba-1 Phase 3, Pancreatic Cancer +8